Table 4.
Coagulation disorders in 24 cases (6 men [on testosterone] and 18 women [on estrogen]) who had testosterone/hormone therapy before PE, compared to 116 cases with PE but no hormone, no cancer (62 men, 54 women), and compared to 17 cancer cases (9 men, 8 women)
| Factor V | PTG | MTHFR | PAIG | Homocys-teinea | Lupus anticoagulant | ACLA IgG | ACLA IgM | |
|---|---|---|---|---|---|---|---|---|
| Abnormal range | TC,TT | TC,TT | TT | 4G4G | umol/l | Positive | Datedb | Datedc |
| Hormone Cases (n = 24, 6 men on TT, 18 women on ET) |
4/24 (17 %) |
2/24 (8 %) |
1/24 (4 %) |
1/24 (4 %) |
3/24 (13 %) |
2/24 (8 %) |
2/24 (8 %) |
2/24 (8 %) |
| PE_no hormone, no Cancer (n = 116, 62 men, 54 women) | 15/105 (14 %) |
7/71 (10 %) |
18/43 (42 %) ** |
17/68 (25 %) |
1/61 (2 %) |
5/58 (9 %) |
||
| Cancer (n = 17, 9 men, 8 women) |
0/15 (0 %) |
6/15 (40 %) |
1/17 (6 %) |
0/15 (0 %) |
1/17 (6 %) |
**p < .025, comparing with Hormone cases by Fisher’s test
adated cut point for Homocysteine high: ≥ 15 (11/15/08-12/2/14); ≥10.4 (after 12/3/14)
bdated cut point for IgG high: ≥ 23 GPL (before 10/31/12); ≥ 15 (after 11/1/12)
cdated cut point for IgM high: ≥ 10 MPL (before 4/30/12); ≥ 13 (after 5/1/12)